Research Assistant –Translational Medicine - Redwood City, CA | Biospace
Get Our FREE Industry eNewsletter

Research Assistant –Translational Medicine

OncoMed Pharmaceuticals Inc.

Redwood City, CA
Posted Date:
Position Type:
Full time
Job Code:
Required Education:
Bachelors Degree
Areas of Expertise Desired:

Job Description

We are looking for a highly motivated researcher that enjoys working in a fast paced work environment. The successful candidate will play an essential role in OncoMed’s Translational Medicine Group working on immunohistochemistry (IHC) based predictive biomarker studies in support of OncoMed’s clinical pipeline. The candidate will report to the Director, Translational Medicine.

•   IHC staining, both manual and automated, on pre-clinical, non-clinical and clinical samples
•   Develop novel IHC assays using internally generated as well as commercially available antibodies
•   Imaging of tissue sections using automated microscopy, database entry, and manual and automated image analysis
•   Tissue sectioning and basic histology techniques


•   Degree in Biological Sciences or related discipline with at least 2 years pharmaceutical industry experience.
•   Experience in histology, including tissue sample preparation, sectioning, special stains and particularly immunohistochemistry is required.
•   Experience in the application of biomarkers towards oncology and immuno-oncology drug development is preferred.
•   Familiarity with tumor pathology, cancer biology and image analysis is preferred.
•   Excellent skills in written and oral communication are required
•   Works well and thrives in a collaborative matrix environment

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis.  Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company's strategic alliances with Celgene Corporation.  OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research.  OncoMed is also evaluating potential partnering opportunities for vantictumab (anti-Fzd, OMP-18R5) and ipafricept (Fzd8-Fc, OMP-54F28).  

Please see the company's website at for additional information.

To apply for this position, please email your CV to indicating the job title you are applying for.